8-substituted b-nor-6-thiaequilenin compounds having activity as selective estrogen receptor modulators
CA 2212204 A1 · Owner: Eli Lilly And Company · Inventors: Lugar, Charles Willis Iii; Dodge, Jeffrey Alan
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Certain B-nor-6-thiaequilenin compounds substituted at the 3-position with hydroxy and at the 8-position with hydroxy or alkoxy of from one to four carbon atoms are selective estrogen receptor modulators and are useful in the treatment of estrogen receptor modulators and are useful in the conditions as osteoporosis, hyperlipidemia estrogen-dependent, breast cancer, uterine fibrosis endometriosis, and, restenosis.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 1, 1997. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended August 1, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 1, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.